Evidence map›Paper›PMID 32045417›Full record

ArticlePloS one2020

A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.

Ângela Carvalho-Gomes, Almudena Cubells, Carmina Pallarés, Vanessa Hontangas, Isabel Conde, Tomasso Di Maira, Salvador Peiró, Gabriel Sanfélix-Gimeno, F Xavier López-Labrador, Marina Berenguer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ângela Carvalho-GomesLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Almudena CubellsLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Carmina PallarésLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Vanessa HontangasLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Isabel CondeLiver Transplantation and Hepatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain.
Tomasso Di MairaLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Salvador PeiróHealth Services Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO Public Health), València, Spain.ORCID 0000-0002-3902-569X
Gabriel Sanfélix-GimenoHealth Services Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO Public Health), València, Spain.
F Xavier López-LabradorVirology Laboratory, Joint Units in Genomics and Health and Infection and Health, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO Public Health) / Universitat de València, València, Spain.ORCID 0000-0002-9403-8258
Marina BerenguerLiver Transplantation and Hepatology Laboratory, Instituto de Investigación Sanitaria La Fe, València, Spain.
Instituto de Investigación Sanitaria La Fe · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESInstituto de Salud Carlos III · ESUniversitat de València · ESHospital Universitari i Politècnic La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on the true prevalence of hepatitis C virus (HCV) infection in the general population is essential. We evaluated a program implementing free universal HCV screening using a non-invasive point-of-care test (POCT) (OraQuick-HCV rapid test) in oral fluid in an urban area in Valencia, South-Eastern Spain.

methodsA cross-sectional study was performed during 2015-2017. Free HCV screening was offered by regular mail to 11,500 individuals aged 18 and over, randomly selected from all census residents in the Health Department. All responding participants filled in a questionnaire about HCV infection risk factors and were tested in their tertiary Hospital. In those with a positive POCT, results were confirmed by enzyme-immunoassay and HCV-RNA.

results1,206 persons agreed to participate (response rate: 11.16%). HCV antibodies were detected in 19 (1.60%) cases (age-sex standardized rate: 1.31%; 95%CI: 0.82-2.07), but only 8 showed positive HCV-RNA (age-sex standardized rate: 0.56%; 95%CI: 0.28-1.14). The majority (89%) of the cases were born before 1965 and 74% had at least one known risk factor for HCV infection. All anti-HCV positive individuals were already aware of their infection, and no undiagnosed cases were detected. The performance of the POCT was excellent for detecting active infection.

conclusionsThese preliminary data suggest that HCV population screening with a POCT is feasible but, in our setting, mailing recruiting is not effective (11% response rate). The low prevalence of HCV antibodies and active infection in the participant population (with no new diagnoses made) suggests that, in our setting, underdiagnosis may be uncommon.

Indexed as

AdolescentAdultAgedAged, 80 and overAntiviral AgentsCross-Sectional StudiesFemaleHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleMiddle AgedPoint-of-Care SystemsPrevalenceRisk FactorsAntiviral AgentsHepatitis C AntibodiesRNA, Viral

Identifiers

PMID32045417
PMCPMC7012430
OpenAlexW3005875005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.